Basic Information
| RNALocate ID: | RLID:11002748 |
| RNA Symbol: | hsa-miR-18b-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-18b-5p |
| RNA ID: | miRBase:MIMAT0001412 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22211110 |
| Tissue/Cell Line: | Breast milk |
| Method: | Next-generation RNA sequencing |
|
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002273 | Cytoplasm | Breast cancer tissue | 32370743 |
| RLID:01002274 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01002275 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01002276 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002277 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:11002747 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11002749 | Exosome | Brain tissue | 23382797 |
| RLID:11002750 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11002751 | Exosome | Serum | 25349172 |
| RLID:11002752 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000450 | Microvesicle | Mesenchymal stem cells | |
| RLID-D:11001225 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-18b-5p | Mantle cell lymphoma | MNDR-E-MI-21905 |
| MNDR | hsa-miR-18b-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-21906 |
| MNDR | hsa-miR-18b-5p | Oral squamous cell carcinoma | MNDR-E-MI-21907 |
| MNDR | hsa-miR-18b-5p | Large cell neuroendocrine cancer | MNDR-E-MI-21908 |
| MNDR | hsa-miR-18b-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-21909 |
| MNDR | hsa-miR-18b-5p | Ovarian clear cell carcinoma | MNDR-E-MI-21910 |
| MNDR | hsa-miR-18b-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-21911 |
| MNDR | hsa-miR-18b-5p | Lymphoma | MNDR-E-MI-21912 |
| MNDR | hsa-miR-18b-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-21913 |
| MNDR | hsa-miR-18b-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-21914 |
| MNDR | hsa-miR-18b-5p | Her2-receptor positive breast cancer | MNDR-E-MI-21915 |
| MNDR | hsa-miR-18b-5p | Prostate cancer | MNDR-E-MI-21916 |
| MNDR | hsa-miR-18b-5p | Gastric cancer | MNDR-E-MI-21917 |
| MNDR | hsa-miR-18b-5p | Alzheimer disease | MNDR-E-MI-21918 |
| MNDR | hsa-miR-18b-5p | Intracranial aneurysm | MNDR-E-MI-21919 |
| MNDR | hsa-miR-18b-5p | Sarcoma | MNDR-E-MI-21920 |
| MNDR | hsa-miR-18b-5p | Dysautonomia familial | MNDR-E-MI-21921 |
| MNDR | hsa-miR-18b-5p | Head and neck cancer | MNDR-E-MI-21922 |
| MNDR | hsa-miR-18b-5p | Leukemia | MNDR-E-MI-21923 |
| MNDR | hsa-miR-18b-5p | Cardiovascular disease | MNDR-E-MI-21924 |
| MNDR | hsa-miR-18b-5p | Lung cancer | MNDR-E-MI-21925 |
| MNDR | hsa-miR-18b-5p | Parkinson disease | MNDR-E-MI-21926 |
| MNDR | hsa-miR-18b-5p | Basal-like breast cancer | MNDR-E-MI-21927 |
| MNDR | hsa-miR-18b-5p | Thyroid cancer | MNDR-E-MI-21928 |
| MNDR | hsa-miR-18b-5p | Pancreatic cancer | MNDR-E-MI-21929 |
| MNDR | hsa-miR-18b-5p | Melanoma | MNDR-E-MI-21930 |
| MNDR | hsa-miR-18b-5p | Nephroblastoma | MNDR-E-MI-21931 |
| MNDR | hsa-miR-18b-5p | Colon cancer | MNDR-E-MI-21932 |
| MNDR | hsa-miR-18b-5p | Colon adenocarcinoma | MNDR-E-MI-21933 |
| MNDR | hsa-miR-18b-5p | Multiple sclerosis | MNDR-E-MI-21934 |
| MNDR | hsa-miR-18b-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-21935 |
| MNDR | hsa-miR-18b-5p | Familial ovarian cancer | MNDR-E-MI-21936 |
| MNDR | hsa-miR-18b-5p | Prostate adenocarcinoma | MNDR-E-MI-21937 |
| MNDR | hsa-miR-18b-5p | Glioblastoma | MNDR-E-MI-21938 |
| MNDR | hsa-miR-18b-5p | Astrocytoma | MNDR-E-MI-21939 |
| MNDR | hsa-miR-18b-5p | Glioma | MNDR-E-MI-21940 |
| MNDR | hsa-miR-18b-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-21941 |
| MNDR | hsa-miR-18b-5p | Osteosarcoma | MNDR-E-MI-21942 |
| MNDR | hsa-miR-18b-5p | Liposarcoma | MNDR-E-MI-21943 |
| MNDR | hsa-miR-18b-5p | Infarction middle cerebral artery | MNDR-E-MI-21944 |
| MNDR | hsa-miR-18b-5p | Stomach adenocarcinoma | MNDR-E-MI-21945 |
| MNDR | hsa-miR-18b-5p | Lung squamous cell carcinoma | MNDR-E-MI-21946 |
| MNDR | hsa-miR-18b-5p | Non-small cell lung adenocarcinoma | MNDR-E-MI-21947 |
| MNDR | hsa-miR-18b-5p | Lung adenocarcinoma | MNDR-E-MI-21948 |
| MNDR | hsa-miR-18b-5p | Thyroid carcinoma | MNDR-E-MI-21949 |
| MNDR | hsa-miR-18b-5p | Ovarian carcinoma | MNDR-E-MI-21950 |
| MNDR | hsa-miR-18b-5p | Pancreatic adenocarcinoma | MNDR-E-MI-21951 |
| MNDR | hsa-miR-18b-5p | Brain stem cancer | MNDR-E-MI-21952 |
| MNDR | hsa-miR-18b-5p | Carcinoma renal cell | MNDR-E-MI-21953 |
| MNDR | hsa-miR-18b-5p | Cholangiocarcinoma | MNDR-E-MI-21954 |
| MNDR | hsa-miR-18b-5p | Esophageal cancer | MNDR-E-MI-21955 |
| MNDR | hsa-miR-18b-5p | Lung small cell carcinoma | MNDR-E-MI-21956 |
| MNDR | hsa-miR-18b-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-21957 |
| MNDR | hsa-miR-18b-5p | T acute lymphoblastic leukemia | MNDR-E-MI-21958 |
| MNDR | hsa-miR-18b-5p | Acute t cell leukemia | MNDR-E-MI-21959 |
| MNDR | hsa-miR-18b-5p | Fibromyalgia | MNDR-E-MI-21960 |
| MNDR | hsa-miR-18b-5p | Hepatocellular carcinoma | MNDR-E-MI-21961 |
| MNDR | hsa-miR-18b-5p | Familiar ovarian carcinoma | MNDR-E-MI-21962 |
| MNDR | hsa-miR-18b-5p | B-cell lymphoma | MNDR-E-MI-21963 |
| MNDR | hsa-miR-18b-5p | Retinoblastoma | MNDR-E-MI-21964 |
| MNDR | hsa-miR-18b-5p | Hodgkin lymphoma | MNDR-E-MI-21965 |
| MNDR | hsa-miR-18b-5p | Colorectal cancer | MNDR-E-MI-21966 |
| MNDR | hsa-miR-18b-5p | Multiple myeloma | MNDR-E-MI-21967 |
| MNDR | hsa-miR-18b-5p | Ependymoma | MNDR-E-MI-21968 |
| MNDR | hsa-miR-18b-5p | Cardiomegaly | MNDR-E-MI-21969 |
| MNDR | hsa-miR-18b-5p | Nasopharyngeal cancer | MNDR-E-MI-21970 |
| MNDR | hsa-miR-18b-5p | Prostatic neoplasms | MNDR-E-MI-21971 |
| MNDR | hsa-miR-18b-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-21972 |
| MNDR | hsa-miR-18b-5p | Stroke lacunar | MNDR-E-MI-21973 |
| MNDR | hsa-miR-18b-5p | Breast cancer her3+ negative | MNDR-E-MI-21974 |
| MNDR | hsa-miR-18b-5p | HPV | MNDR-E-MI-21975 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CCN2 | Homo sapiens | RR00294323 |
TOP